Progress-free.

This data confirms what we all know in our hearts to be true. The vast majority (89%) of clinical trials evaluating systemic cancer therapy are funded by industry with a concurrent rise in progression-free, rather than overall, survival as a primary endpoint, increasing from 0% to 42% over the past two decades (figure 2 really says it all). | Del Paggio, JAMA Oncol 2022